Vaccination Against COVID-19 in Chronic Kidney Disease

Status Recruiting

Clinical Trial Summary

This is a prospective, multi-center, observational study that will enroll patients receiving dialysis (hemodialysis or peritoneal dialysis) or patients with kidney transplantation who will be vaccinated against COVID-19.

Clinical Trial Description

Patients on dialysis and kidney transplant patients infected with SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2) have an increased risk to develop a more severe course of disease or die from COVID-19 (coronavirus disease 2019). SARS-CoV-2 vaccination can increase protection against COVID-19. Kidney transplant patients and patients requiring dialysis suffer from an acquired immune deficiency. Due to the dysfunctional immune response, the general vaccine response in dialysis patients and kidney transplant patients is in many cases insufficient. Until now, the vaccination response in dialysis patients and kidney-transplanted patients is unpredictable. Verification of vaccine response can provide important information on how to treat and protect these patients from a COVID-19. Therefore, there is a medical need to monitor vaccine protection after SARS-CoV-2 vaccination in clinical practice. In this observational study, data of the SARS-CoV-2 vaccination response collected in clinical routine will be analyzed from these patients. Based on this observational study, the investigators aim to get first evidence whether and to what extent vaccination against COVID-19 causes a vaccine response in immunocompromised patients with kidney disease. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04743947
Study type	Observational
Source	Heinrich-Heine University, Duesseldorf
Contact	Johannes Stegbauer, MD
Phone	+492118117502
Email	johannes.stegbauer@med.uni-duesseldorf.de
Status	Recruiting
Phase
Start date	December 21, 2020
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05060991` - Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients	Phase 4
Active, not recruiting	`NCT01446978` - Three Doses of Hepatitis A Vaccine in Patients With Immunomodulating Drugs	Phase 2
Completed	`NCT03855176` - Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients	Phase 4
Not yet recruiting	`NCT05923970` - Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
Recruiting	`NCT05019248` - Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
Completed	`NCT03467074` - Role of Interferon-λ and Vaccine Response
Completed	`NCT05124509` - Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant
Completed	`NCT05791851` - Heplisav-B Revaccination for Hepatitis B Vaccine Nonresponders
Completed	`NCT05030974` - RECOVAC Repeated Vaccination Study	Phase 4
Completed	`NCT03930017` - Pregnancy, Arsenic and Immune Response
Completed	`NCT05116748` - COVID19 Vaccine in SOT Adult Recipients
Recruiting	`NCT06148025` - Antibiotics and Vaccine Immune Responses Study	Phase 4
Completed	`NCT03368495` - Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines	Phase 4
Completed	`NCT04059991` - Antibodies in Repeated Influenza Vaccination (ARIVA) Study
Completed	`NCT04915820` - Iron and COVID-19 Vaccine Response	N/A
Completed	`NCT04912661` - Iron and Vaccine Response	N/A
Completed	`NCT04885907` - Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients	Phase 4
Completed	`NCT03588013` - Study of Environmental Enteropathy and Malnutrition in Pakistan	N/A
Completed	`NCT04936997` - Immune Response to the COVID-19 Vaccine	Early Phase 1
Completed	`NCT03996538` - Vaccination Efficacy With Metformin in Older Adults	Phase 1